Amelioration of Tau and ApoE4-linked glial lipid accumulation and neurodegeneration with an LXR agonist

Neuron, Journal Year: 2023, Volume and Issue: 112(3), P. 384 - 403.e8

Published: Nov. 22, 2023

Language: Английский

---

Passive immunotherapy for Alzheimer's disease

Ageing Research Reviews, Journal Year: 2024, Volume and Issue: 94, P. 102192 - 102192

Published: Jan. 14, 2024

Alzheimer's disease (AD) is the most common neurodegenerative characterized by cognitive impairment with few therapeutic options. Despite many failures in developing AD treatment during past 20 years, significant advances have been achieved passive immunotherapy of very recently. Here, we review characteristics, clinical trial data, and mechanisms action for monoclonal antibodies (mAbs) targeting key players pathogenesis, including amyloid-β (Aβ), tau neuroinflammation modulators. We emphasized efficacy lecanemab donanemab on cognition amyloid clearance patients phase III trials discussed factors that may contribute to side effects anti-Aβ mAbs. In addition, provided important information mAbs or inflammatory regulators trials, indicated against mid-region pathogenic potential AD. conclusion, pathogenesis offers a promising strategy effective treatment.

Language: Английский

---

Biological function of sialic acid and sialylation in human health and disease

Cell Death Discovery, Journal Year: 2024, Volume and Issue: 10(1)

Published: Sept. 30, 2024

Language: Английский

---

Monocyte-derived macrophages act as reinforcements when microglia fall short in Alzheimer’s disease

Nature Neuroscience, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 6, 2025

Language: Английский

---

The case for low-level BACE1 inhibition for the prevention of Alzheimer disease

Nature Reviews Neurology, Journal Year: 2021, Volume and Issue: 17(11), P. 703 - 714

Published: Sept. 21, 2021

Language: Английский

---